| Bioactivity | AZD9898 is an orally active leukotriene-C4 synthetase (LTC4S, glutathione S-transferase II) inhibitor, with an IC50 of 0.28 nM. AZD9898 mitigates the GABA binding and hepatic toxicity signal. AZD9898 has the potential to treat asthma[1]. | ||||||||||||
| Target | IC50: 0.28 nM (LTC4S). | ||||||||||||
| In Vivo | AZD9898 with the single dose of 100 mg/kg is well tolerated and no safety concerns are raised[1]. Animal Model: | ||||||||||||
| Name | AZD9898 | ||||||||||||
| CAS | 2042347-69-1 | ||||||||||||
| Formula | C20H19ClF3N3O4 | ||||||||||||
| Molar Mass | 457.83 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Munck Af Rosenschöld M, et al. Discovery of the Oral Leukotriene C4 Synthase Inhibitor (1S,2S)-2-({5-[(5-Chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino]-3-methoxypyrazin-2-yl}carbonyl)cyclopropanecarboxylic Acid (AZD9898) as a New Treatment for |
AZD9898
CAS: 2042347-69-1 F: C20H19ClF3N3O4 W: 457.83
AZD9898 is an orally active leukotriene-C4 synthetase (LTC4S, glutathione S-transferase II) inhibitor, with an IC50 of 0
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.